Crizotinib is most commonly used to treat non-small cell lung cancer (NSCLC) that is positive for ALK or ROS1 gene rearrangements. Additionally, it has shown effectiveness in treating other cancers with these genetic alterations, such as certain types of lymphomas and inflammatory myofibroblastic tumors (IMTs).
